Smith & Nephew plc (SNN) Stock: Price, Forecast & Analyst Target
Smith & Nephew plc (SNN) — MoonshotScore 87/100 (Exceptional band), calculated Oct 5, 2026. Price $26.97 (+2.08%), as of the Oct 5, 2026 trading session; market cap $11.3B. Expected results Feb 23, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 14.99× (market value Oct 5, 2026; cash Jun 27, 2026) · expected results Feb 23, 2027
Smith & Nephew plc · SNN · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-13: Smith & Nephew supplies healthcare providers with joint implants, trauma systems, arthroscopy equipment, ear, nose and throat solutions, and advanced wound products; it is a procedural medical-device platform, not merely a maker of replacement joints. Product launches must now offset competitive pressure in the United States while higher profit becomes dependable cash generation.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Smith & Nephew (SNN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and elite growth, at a cheap price, though the balance sheet is only middling. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Quiet.
- quarterly revenue $3.10B (Q2 FY2026, quarter ended Jun 27, 2026)
- EPS beat 4 of 8
- Altman Z 3.76 · Piotroski F 8
Helping: business quality, an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional |
The score was 87 in the stored Oct 4, 2026 snapshot and remains 87 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $26.97 | |
| Change on the day | +2.08% | |
| 52-week range | $26.12 – $37.51 | |
| Market capitalisation | $11.3B | |
| Price / earnings (trailing) | 17.54 | |
| Shares traded on the day | 1.4M | |
| Beta (volatility vs the S&P 500) | 0.69 | |
| Dividends per share (last 12 months) | $0.79 | |
| Dividend yield (last 12 months) | 3.01% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Now taking into account revenue performance, we now expect underlying revenue growth of around 4% for 2026.
Deepak Nath · Statement from
We are seeing the impact of competitor launches in the U.S., but we expect growth to strengthen in the second half as we launch EVOS, Pelvic and ramp up TRIGEN MAX.
John Rogers · Statement from
Chronological order, not a duration scale. Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Smith & Nephew (SNN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the SNN film — every key number, told as a short cinematic story
~2 min · open the film
What is Smith & Nephew (SNN), and what does it report?
Short answer · as of
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.
Research dated 2026-09-13.
Demand comes from procedures and wound treatment: healthcare providers buy implants and fracture-stabilization systems, instruments and visualization equipment for minimally invasive surgery, and products used across acute, chronic and postoperative wounds.
Reported sales place orthopaedics, sports medicine, and ear, nose and throat products in a combined category, with Advanced Wound Management reported separately. Most revenue comes from the combined category, so consolidated growth primarily reflects surgical devices even though wound care remains a meaningful business.
What do the latest results show for Smith & Nephew (SNN)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $3.10B.
Research dated 2026-09-13.
Annual revenue and net income have advanced across recent reporting periods, and the latest comparable-period figures continued that pattern. Revenue rose, gross profit and operating profit increased, and net income edged higher, although revenue was below the immediately preceding period. Reported earnings have also cleared estimates lately after earlier misses.
Management attributes current pressure in the United States to competitor launches and expects EVOS, Pelvic, and TRIGEN MAX to strengthen growth as their rollouts progress. That is a management expectation rather than an explanation already established by the reported results.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $3.10B Jun 27, 2026
- Latest quarter · R&D
- $150.00M Jun 27, 2026
- Latest quarter · SG&A
- $1.60B Jun 27, 2026
- Latest quarter · FMP standardized operating result
- $448.00M Jun 27, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 27, 2026 | $3.10B | $150.00M | $1.60B | $448.00M |
| Dec 31, 2025 | $3.20B | $203.00M | $1.52B | $365.00M |
| Jun 30, 2025 | $2.96B | $143.00M | $1.52B | $429.00M |
| Dec 31, 2024 | $2.98B | $206.00M | $1.40B | $329.00M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $3.10B Aug 4, 2026
- Latest report · revenue estimate
- $1.64B Aug 4, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 4, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 4, 2026 | $3.10B | $1.64B | $0.9460 | $0.9390 |
| Mar 2, 2026 | $3.20B | $2.77B | $1.1800 | $1.1600 |
| Aug 5, 2025 | $2.96B | $1.53B | $0.8580 | $0.7900 |
| Feb 25, 2025 | $2.98B | $2.96B | $0.9380 | $0.9200 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $3.10B | $303M | $0.70 (diluted) |
| Q4 FY2025 | $3.20B | $332M | $0.76 (diluted) |
| Q2 FY2025 | $2.96B | $293M | $0.68 (diluted) |
| Q4 FY2024 | $2.98B | $198M | $0.46 (diluted) |
What are the financial strengths and risks for Smith & Nephew (SNN)?
Short answer
Cash and short-term investments were $754.00M at the Jun 27, 2026 balance-sheet date. Operating cash flow was $450.00M for the quarter ended Jun 27, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow has stayed positive throughout the displayed series, and recent generation remained above capital spending. Cash and short-term investments have also recovered to the highest point in that series, while liquidity ratios and quality screens indicate a sound near-term financial footing.
Debt still substantially exceeds cash and investments, leaving Smith & Nephew dependent on continued cash conversion rather than balance-sheet cash alone. Competitive pressure that slows surgical-device growth, or weaker working-capital performance while restructuring costs rise, would reduce the cash available for debt service and distributions.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $450.00M Jun 27, 2026
- Previous quarter · operating cash flow
- $889.00M Dec 31, 2025
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 27, 2026 | $450.00M | −$190.00M |
| Dec 31, 2025 | $889.00M | −$294.00M |
| Jun 30, 2025 | $396.00M | −$139.00M |
| Dec 31, 2024 | $749.00M | −$209.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Smith & Nephew (SNN)?
Short answer · as of
The next earnings report is expected on Feb 23, 2027.
Research dated 2026-09-13.
The scheduled earnings update needs to pair continued revenue expansion with evidence that EVOS, Pelvic, and TRIGEN MAX are gaining traction against competitor launches in the United States. Consensus estimates assume further sales and earnings growth, raising the importance of execution in the combined surgical-device portfolio.
Cash conversion deserves equal attention. Management expects profit growth and working-capital discipline to support free cash flow despite a temporary increase in restructuring costs; operating cash flow, capital spending, and the cash balance will show whether that bridge is holding. Recent broker downgrades add context to the execution test without determining its outcome.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Now taking into account revenue performance, we now expect underlying revenue growth of around 4% for 2026.
Deepak Nath ·
We are seeing the impact of competitor launches in the U.S., but we expect growth to strengthen in the second half as we launch EVOS, Pelvic and ramp up TRIGEN MAX.
John Rogers ·
We continue to expect free cash flow in 2026 of around $800 million, driven by profit growth and continued focus on working capital, offset by a modest temporary increase in restructuring costs.
John Rogers ·
What the records here don't tell us
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Smith & Nephew compare with its peers?
Short answer
Smith & Nephew's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Compared with a device maker concentrated on joint reconstruction, Smith & Nephew reaches further across the procedure: implants and trauma hardware sit alongside arthroscopy tools, visualization systems, tissue-resection equipment, and ear, nose and throat products. Advanced Wound Management adds exposure to wound dressings, bioactive products, negative-pressure therapy, and hydrosurgery.
That breadth can spread demand across surgical and wound-care settings, but the reporting structure combines several surgical franchises into a large category. Investors therefore see less divisional detail than the product range itself might suggest.
| Company | Price | Market value | Score |
|---|---|---|---|
| $76.57 Oct 5, 2026 | $10.4B | 96 5-pillar Oct 5, 2026 | |
| $317.11 Oct 5, 2026 | $12.5B | 95 5-pillar Oct 5, 2026 | |
| $144.21 Oct 5, 2026 | $14.5B | 92 5-pillar Oct 5, 2026 | |
| $620.51 Oct 5, 2026 | $16.7B | 92 5-pillar Oct 5, 2026 | |
| Smith & Nephew (SNN) — this page | $26.97 | $11.3B | 87 |
| $211.07 Oct 5, 2026 | $20.3B | 87 5-pillar Oct 5, 2026 | |
| $140.65 Oct 5, 2026 | $9.98B | 83 5-pillar Oct 5, 2026 | |
| $135.62 Oct 5, 2026 | $9.09B | 83 5-pillar Oct 5, 2026 | |
| $91.57 Oct 5, 2026 | $17.7B | 80 5-pillar Oct 5, 2026 | |
| $23.91 Oct 5, 2026 | $23.4B | 74 5-pillar Oct 5, 2026 | |
| $56.66 Oct 5, 2026 | $25.3B | 73 5-pillar Oct 5, 2026 | |
| $64.30 Oct 5, 2026 | $31.8B | 71 5-pillar Oct 5, 2026 | |
| $63.86 Oct 5, 2026 | $9.63B | 59 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $30.00 – $33.88
- Consensus target
- $31.91
- Median target
- $31.85
Consensus record · Captured .
Measured against a quoted price of $26.97 (as of Oct 5, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 8.5% Period end Jun 30, 2026
- Previous quarter · ownership
- 7.4% Prior to period end Jun 30, 2026
- Reporting holders
- 295 Period end Jun 30, 2026
- Previous quarter · holders
- 280 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| River Road Asset Management, LLC | 3,221,876 |
| Goldman Sachs Group INC | 3,069,598 |
| Brandes Investment Partners, LP | 2,148,731 |
| Dimensional Fund Advisors LP | 1,837,261 |
| Lmr Partners Llp | 1,767,872 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Smith & Nephew (SNN)?
What Investors Ask About Smith & Nephew (SNN) — Healthcare
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Smith & Nephew sell beyond hip and knee implants?
The portfolio includes trauma and extremities systems, arthroscopy instruments and visualization equipment, tissue-resection devices, ear, nose and throat solutions, wound dressings, bioactive products, negative-pressure therapy, and hydrosurgery systems.
Why do EVOS, Pelvic, and TRIGEN MAX matter to Smith & Nephew?
Management has tied these launches and product ramps to an expected improvement in United States growth after competitor launches pressured performance. Their commercial progress is therefore a direct test of the stated recovery mechanism.
How important is Advanced Wound Management to Smith & Nephew?
Advanced Wound Management is a substantial but smaller revenue stream than the combined orthopaedics, sports medicine, and ear, nose and throat category. It broadens the company beyond implants through wound care, bioactives, regenerative products, and treatment devices.
Can Smith & Nephew operating cash flow support its dividend and debt load?
Recent operating cash flow has covered capital spending, and distributions have continued, but debt remains well above cash and investments. Ongoing support therefore depends on sustained cash conversion, including the working-capital improvement management expects.
What is the SNN stock price today?
The last price recorded on this page for Smith & Nephew plc (SNN) is $26.97, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SNN price target?
The analyst consensus price target for Smith & Nephew plc (SNN) is $31.91 (range $30.00 to $33.88, median $31.85), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (85 figures)
The 85 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Deepak Nath (Aug 4, 2026): Now taking into account revenue performance, we now expect underlying revenue growth of around 4% for 2026. John Rogers (Aug 4, 2026): We are seeing the impact of competitor launches in the U.S., but we expect growth to strengthen in the second half as we launch EVOS, Pelvic and ramp up TRIGEN MAX. John Rogers (Aug 4, 2026): We continue to expect free cash flow in 2026 of around $800 million, driven by profit growth and continued focus on working capital, offset by a modest temporary increase in restructuring costs. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Building 5, Croxley Park, Hatters Lane, Watford, Hertfordshire, WD18 8YE | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Building 5 Croxley Park Hatters Lane, Watford, HRT, WD18 8YE, GB". |
FMP — 73 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Feb 23, 2027 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $26.97 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T18:50:03.000Z. | |
px.change | Change on the day | +2.08% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $11.3B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T18:50:03.000Z. Captured from FMP at 2026-10-05T18:50:10.511Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.55 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $3.10B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 17.54 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.4M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.69 | FMP | Financial Modeling Prep (FMP) company profile | |
id.business_summary | Business description (FMP excerpt) | Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
id.ceo | Chief executive | Deepak S. Nath | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 18,362 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $5.21B, net result $524.00M; FY2022 revenue $5.21B, net result $223.00M; FY2023 revenue $5.55B, net result $263.00M; FY2024 revenue $5.81B, net result $412.00M; FY2025 revenue $6.16B, net result $625.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Advanced Wound Management $1.79B · Orthopaedics, Sports Medicine and Ear Nose and Throat $4.37B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 68.2% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-27.revenue_k | Revenue — period end 2026-06-27 | $3.10B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-27.rd_k | R&D — period end 2026-06-27 | $150.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-27.sga_k | SG&A — period end 2026-06-27 | $1.60B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-27.operating_result_k | FMP standardized operating result — period end 2026-06-27 | $448.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $3.20B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $203.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $1.52B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $365.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.revenue_k | Revenue — period end 2025-06-30 | $2.96B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.rd_k | R&D — period end 2025-06-30 | $143.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.sga_k | SG&A — period end 2025-06-30 | $1.52B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.operating_result_k | FMP standardized operating result — period end 2025-06-30 | $429.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.revenue_k | Revenue — period end 2024-12-31 | $2.98B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.rd_k | R&D — period end 2024-12-31 | $206.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.sga_k | SG&A — period end 2024-12-31 | $1.40B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.operating_result_k | FMP standardized operating result — period end 2024-12-31 | $329.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-04.revenue_actual | Revenue · reported — report date 2026-08-04 | $3.10B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.revenue_estimated | Revenue · estimate — report date 2026-08-04 | $1.64B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_actual | EPS · reported — report date 2026-08-04 | $0.9460 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_estimated | EPS · estimate — report date 2026-08-04 | $0.9390 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-02.revenue_actual | Revenue · reported — report date 2026-03-02 | $3.20B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-02.revenue_estimated | Revenue · estimate — report date 2026-03-02 | $2.77B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-02.eps_actual | EPS · reported — report date 2026-03-02 | $1.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-02.eps_estimated | EPS · estimate — report date 2026-03-02 | $1.1600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-05.revenue_actual | Revenue · reported — report date 2025-08-05 | $2.96B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-05.revenue_estimated | Revenue · estimate — report date 2025-08-05 | $1.53B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-05.eps_actual | EPS · reported — report date 2025-08-05 | $0.8580 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-05.eps_estimated | EPS · estimate — report date 2025-08-05 | $0.7900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-25.revenue_actual | Revenue · reported — report date 2025-02-25 | $2.98B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-25.revenue_estimated | Revenue · estimate — report date 2025-02-25 | $2.96B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-25.eps_actual | EPS · reported — report date 2025-02-25 | $0.9380 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-25.eps_estimated | EPS · estimate — report date 2025-02-25 | $0.9200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $754.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $450.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-27. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $151.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $3.79B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 2.15× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-27.operating_cash_flow_m | Operating cash flow — period end 2026-06-27 | $450.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $889.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-27.capex_m | Capital expenditure (reported) — period end 2026-06-27 | −$190.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$294.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-06-30.operating_cash_flow_m | Operating cash flow — period end 2025-06-30 | $396.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-06-30.capex_m | Capital expenditure (reported) — period end 2025-06-30 | −$139.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2024-12-31.operating_cash_flow_m | Operating cash flow — period end 2024-12-31 | $749.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2024-12-31.capex_m | Capital expenditure (reported) — period end 2024-12-31 | −$209.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $30.00 – $33.88 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $31.91 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $31.85 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.institutions.depth.ownership_pct | Institutional ownership | 8.5% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 7.4% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 295 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 280 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | River Road Asset Management, LLC — shares in provider snapshot | 3,221,876 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Goldman Sachs Group INC — shares in provider snapshot | 3,069,598 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Brandes Investment Partners, LP — shares in provider snapshot | 2,148,731 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Dimensional Fund Advisors LP — shares in provider snapshot | 1,837,261 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Lmr Partners Llp — shares in provider snapshot | 1,767,872 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-08-28 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 3.76 · Piotroski F 8 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $26.12 – $37.51 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 14.99× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $754.00M at Jun 27, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-27. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.79 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 3.01% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-04.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($3.10B) with the recorded estimate ($1.64B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-04.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.9460) with the recorded estimate ($0.9390) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 87 of 100 · Exceptional · pillars 92 / 54 / 78 / 91 / 45 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 87 (stored snapshot Oct 4, 2026) → 87 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-27. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-27.revenue_k,fin.q_table.depth.2026-06-27.rd_k,fin.q_table.depth.2026-06-27.sga_k,fin.q_table.depth.2026-06-27.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-06-30.revenue_k,fin.q_table.depth.2025-06-30.rd_k,fin.q_table.depth.2025-06-30.sga_k,fin.q_table.depth.2025-06-30.operating_result_k,fin.q_table.depth.2024-12-31.revenue_k,fin.q_table.depth.2024-12-31.rd_k,fin.q_table.depth.2024-12-31.sga_k,fin.q_table.depth.2024-12-31.operating_result_k. - Earnings-history note. Source series as of 2026-08-04. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-04.revenue_actual,earn.history.depth.2026-08-04.revenue_estimated,earn.history.depth.2026-08-04.revenue_actual.comparison,earn.history.depth.2026-08-04.eps_actual.comparison,earn.history.depth.2026-08-04.eps_actual,earn.history.depth.2026-08-04.eps_estimated,earn.history.depth.2026-03-02.revenue_actual,earn.history.depth.2026-03-02.revenue_estimated,earn.history.depth.2026-03-02.eps_actual,earn.history.depth.2026-03-02.eps_estimated,earn.history.depth.2025-08-05.revenue_actual,earn.history.depth.2025-08-05.revenue_estimated,earn.history.depth.2025-08-05.eps_actual,earn.history.depth.2025-08-05.eps_estimated,earn.history.depth.2025-02-25.revenue_actual,earn.history.depth.2025-02-25.revenue_estimated,earn.history.depth.2025-02-25.eps_actual,earn.history.depth.2025-02-25.eps_estimated. - Cash-flow note. Source series as of 2026-06-27. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-27.operating_cash_flow_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2026-06-27.capex_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-06-30.operating_cash_flow_m,fin.opcf.depth.2025-06-30.capex_m,fin.opcf.depth.2024-12-31.operating_cash_flow_m,fin.opcf.depth.2024-12-31.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | SMITH & NEPHEW PLC Our market-data provider lists the name as "Smith & Nephew plc"; the filer's own record is used here. | 2026-09-13 | OFFICIAL | SEC EDGAR filer record |
| Business description | Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Management outlook — dated call excerpts | Captured record · 3 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-04 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Revenue by segment | Advanced Wound Management: $1.79B; Orthopaedics, Sports Medicine and Ear Nose and Throat: $4.37B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Devices The company's SEC filings classify it under SIC 3842 — Orthopedic, Prosthetic & Surgical Appliances & Supplies. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-04 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash, investments and debt | Total debt: $3.79B; Liquidity basis: cash and short-term investments; Total liabilities: $5.83B; Cash and short-term investments: $754.00M; Cash and investments: $905.00M; Long-term investments: $151.00M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $905.00M; Cash and short-term investments: $754.00M; Long-term investments: $151.00M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-27 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-06-27; Cash basis: cash and short-term investments; Net cash: -$3.03B; Total debt: $3.79B; Cash and investments: $754.00M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-27 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 1.11; Current ratio: 2.14; Debt to equity: 0.73; Net margin: 10.1%; Gross margin: 68.2%; Operating margin: 16.7%; Return on assets: 5.8%; Return on equity: 12.2% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 3.82; Piotroski F-score: 8 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Next earnings report | Date: 2027-02-23; EPS estimate: $1.21 per share; Revenue estimate: $3.32B The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Analyst actions, most recent per firm | Captured record · 10 entries
One row per firm — the firm's most recent action in our feed. Other data vendors may carry firms ours does not. | 2026-08-06 | FMP | Financial Modeling Prep (FMP) analyst grades |
| Recent dividends paid | Captured record · 4 entries
Declared amounts per share on their ex-dates. A single payment does not establish an annual rate, and a special dividend is not separated here. | 2026-03-27 | FMP | Financial Modeling Prep (FMP) dividend history |
| Next scheduled dividend | Ex date: 2026-10-02; Declared on: 2026-08-04; Record date: 2026-10-02; Payment date: 2026-11-06; Amount per share: $0.31 Amount is per share as declared, before any withholding. Owning the share before the ex-date is what carries entitlement. | 2026-08-04 | FMP | Financial Modeling Prep (FMP) dividend calendar |
Data provided for informational purposes only.